IDS and mucopolysaccharidosis type 2: Consequently, ERT with recombinant human iduronate sulfatase (Elaprase, idursulfase, Shire Human Genetic Therapies Inc.)was approved in the US (July, 2006) and the European Union (January, 2007) for the treatment and the management of MPS II.